The company's development pipeline is focused on three main areas: rare genetic and metabolic disorders, rare connective tissue disorders, and rare lung diseases. With core expertise in drug delivery systems and drug repurposing, the clinical pipeline includes innovative treatments for rare dermatological, metabolic and respiratory conditions, with several approved products brought to market through licensing and distribution partnerships.
Cyborg Score Rationale
As of January 2026, the stock was trading at $1.78 with a market cap of approximately $45.3M, indicating a small-cap biotech. The recent merger with NeuroX (December 2025) introduces digital neurotherapeutics but lacks clear near-term revenue catalysts or profitability milestones evident in public filings.
Top Insights
(November 2025) Shareholders approved business combination with NeuroX creating MindMaze Therapeutics Holding SA
(December 2025) Business combination completed, forming combined digital neurotherapeutics and biopharmaceutical entity
Core expertise in drug delivery systems and repurposing for rare dermatological, metabolic, and respiratory diseases
Limited public disclosure on recent clinical trial data or regulatory milestones; small market capitalization (~$45M)
Named Competitors
Santhera Pharmaceuticals — Rare disease biopharmaceutical company
Idorsia — Small molecule drug development for rare diseases
Genfit — Metabolic disorder drug developer
DBV Technologies — Rare allergy and immunology treatments
Recent Developments
(December 2025) Completed business combination with NeuroX, forming MindMaze Therapeutics Holding SA
(November 2025) Shareholders approved business combination with NeuroX Group SA
(October 2025) Reported positive bioequivalence study results for PKU treatment
Open the full interactive Relief Therapeutics Holding SA (now MindMaze Therapeutics Holding SA) report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.